Zacks Investment Research lowered shares of Nabriva Therapeutics AG (NASDAQ:NBRV) from a buy rating to a hold rating in a research report released on Tuesday morning.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
Other analysts have also issued research reports about the company. HC Wainwright initiated coverage on Nabriva Therapeutics AG in a research note on Thursday, September 8th. They set a buy rating and a $16.00 price objective on the stock. Leerink Swann reaffirmed an outperform rating and set a $14.00 price objective on shares of Nabriva Therapeutics AG in a research note on Thursday, October 27th. Finally, Wedbush reiterated an outperform rating and set a $17.00 target price on shares of Nabriva Therapeutics AG in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $13.15.
Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 4.22 on Tuesday. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $10.69. The stock’s 50 day moving average price is $0.00 and its 200-day moving average price is $0.00.
Institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP purchased a new position in Nabriva Therapeutics AG during the third quarter worth approximately $2,468,000. Opaleye Management Inc. increased its position in Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock worth $2,453,000 after buying an additional 53,800 shares during the period. Finally, Jackson Park Capital LLC purchased a new position in Nabriva Therapeutics AG during the second quarter worth approximately $195,000. Institutional investors own 63.09% of the company’s stock.
About Nabriva Therapeutics AG
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).